• 대한상한금궤의학회지
• /
• v.13 no.1
• /
• pp.189-196
• /
• 2021

Objective : This study aimed to report the improvement of a patient with chronic rhinitis treated with herbal medication using the disease pattern identification diagnostic system (DPIDS) based on the Shanghanlun provisions. Methods : According to the Shanghanlun DPIDS and an etymological interpretation of Chinese characters, the patient was diagnosed with Reverting yin disease (provision 352) and took Dangguisayeokgaosuyusaengang-tang herbal medication for 50 days. The change in symptoms of chronic rhinitis were estimated using the Total Nasal Symptom Score (TNSS), the Rhinitis Control Assessment Test (RCAT), and a visual analog scale (VAS). Results : The TNSS score decreased from 8 to 3, the RCAT score decreased from 14 to 24, and the VAS decreased from 10 to 2. Conclusions : The main causes of the disease were 厥 and 內. This is the first case report of describing the treatment of chronic rhinitis with Dangguisayeokgaosuyusaengang-tang.

• Allergy, Asthma & Immunology Research
• /
• v.10 no.6
• /
• pp.675-685
• /
• 2018

Purpose: This study aims to determine the efficacy and safety of house dust mite (HDM)-sublingual immunotherapy (SLIT) in elderly patients with AR. Methods: A total of 45 patients aged ${\geq}60years$ with HDM-induced AR who had ${\geq}3$ A/H ratio on skin prick test and/or ${\geq}0.35IU/L$ to both Dermatophagoides farinae and Dermatophagoides pteronyssinus by ImmunoCAP were enrolled in 4 university hospitals. To evaluate additional effects of HDM-SLIT, they were randomized to the SLIT-treated group (n = 30) or control group (n = 15). Rhinoconjunctivitis total symptom score (RTSS), rhinoscopy score, Korean rhinoconjunctivitis quality of life questionnaire, rhinitis control assessment test, asthma control test scores, and adverse reactions, were assessed at the first visit (V1) and after 1 year of treatment (V5); for immunological evaluation, serum levels of HDM-specific immunoglobulin A/IgE/IgG1/IgG4 antibodies and basophil response to HDMs were compared between V1 and V5 in both groups. Results: There were no significant differences in demographics, RTSS, skin reactivity to HDMs, or serum total/specific IgE levels to HDMs (P > 0.05, respectively) between the 2 groups. Nasal symptom score and RTSS decreased significantly at year 1 in the 2 groups (P < 0.05). There were no significant differences in percent decrease in nasal symptom score and RTSS at year 1 between the 2 groups (P > 0.05); however, rhinoscopic nasal symptom score decreased significantly in the SLIT-treated group (P < 0.05). Immunological studies showed that serum specific IgA levels (not specific IgE/IgG) and CD203c expression on basophils decreased significantly at V5 in the SLIT-treated group (P = 0.011 and P = 0.001, respectively), not in the control group. The control group required more medications compared to the treatment group, but there were no differences in adverse reactions. Conclusions: It is suggested that HDM-SLIT for 1 year could induce symptom improvement and may induce immunomodulation in elderly rhinitis patients.